Erasmus MC

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

Medical

LBCL | April 04, 2022

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS; hazard ratio 0.398; P< 0.0001) over the cur...

Industrial Impact

OMass Therapeutics | February 21, 2022

OMass Therapeutics a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below. “As we develop our unique drug discovery platform, OdyssION™, and progress our pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bou...

Cell and Gene Therapy

BOSTON LABS | September 23, 2021

Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. announced their partnership to launch a new network of mobile CGT manufacturing facilities. The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver CGT point-of-care contract manufacturing services. The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network ...